JP2007506417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506417A5 JP2007506417A5 JP2006527354A JP2006527354A JP2007506417A5 JP 2007506417 A5 JP2007506417 A5 JP 2007506417A5 JP 2006527354 A JP2006527354 A JP 2006527354A JP 2006527354 A JP2006527354 A JP 2006527354A JP 2007506417 A5 JP2007506417 A5 JP 2007506417A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- tumor
- associated antigen
- antibody
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 113
- 108020004707 nucleic acids Proteins 0.000 claims 103
- 102000039446 nucleic acids Human genes 0.000 claims 103
- 206010028980 Neoplasm Diseases 0.000 claims 59
- 239000000427 antigen Substances 0.000 claims 55
- 102000036639 antigens Human genes 0.000 claims 55
- 108091007433 antigens Proteins 0.000 claims 55
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 230000000295 complement effect Effects 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 239000000032 diagnostic agent Substances 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001037 lung lymphoma Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001875 tumorinhibitory effect Effects 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344799.7 | 2003-09-26 | ||
| DE10344799A DE10344799A1 (de) | 2003-09-26 | 2003-09-26 | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| PCT/EP2004/010697 WO2005030250A2 (de) | 2003-09-26 | 2004-09-23 | Identifizierung von tumorassoziierten zelloberflächen-antigenen für die diagnose und therapie |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011253535A Division JP5639989B2 (ja) | 2003-09-26 | 2011-11-21 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2012223869A Division JP5804519B2 (ja) | 2003-09-26 | 2012-10-09 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007506417A JP2007506417A (ja) | 2007-03-22 |
| JP2007506417A5 true JP2007506417A5 (OSRAM) | 2007-11-08 |
| JP5144933B2 JP5144933B2 (ja) | 2013-02-13 |
Family
ID=34306102
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527354A Expired - Lifetime JP5144933B2 (ja) | 2003-09-26 | 2004-09-23 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2011253535A Expired - Lifetime JP5639989B2 (ja) | 2003-09-26 | 2011-11-21 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2012223869A Expired - Lifetime JP5804519B2 (ja) | 2003-09-26 | 2012-10-09 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2014113690A Expired - Lifetime JP5969538B2 (ja) | 2003-09-26 | 2014-06-02 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2016094337A Expired - Lifetime JP6196350B2 (ja) | 2003-09-26 | 2016-05-10 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011253535A Expired - Lifetime JP5639989B2 (ja) | 2003-09-26 | 2011-11-21 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2012223869A Expired - Lifetime JP5804519B2 (ja) | 2003-09-26 | 2012-10-09 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2014113690A Expired - Lifetime JP5969538B2 (ja) | 2003-09-26 | 2014-06-02 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
| JP2016094337A Expired - Lifetime JP6196350B2 (ja) | 2003-09-26 | 2016-05-10 | 診断および治療のための腫瘍関連細胞表面抗原の同定 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US7875424B2 (OSRAM) |
| EP (22) | EP2266608B1 (OSRAM) |
| JP (5) | JP5144933B2 (OSRAM) |
| AU (1) | AU2004275500B2 (OSRAM) |
| CA (4) | CA2539837C (OSRAM) |
| DE (1) | DE10344799A1 (OSRAM) |
| ES (1) | ES2634705T3 (OSRAM) |
| WO (1) | WO2005030250A2 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| KR20060090715A (ko) * | 2003-09-29 | 2006-08-14 | 추가이 세이야쿠 가부시키가이샤 | Ｎｋ 세포에 발현하는 단백질 |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005013846A1 (de) * | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| WO2007013575A2 (en) * | 2005-07-28 | 2007-02-01 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8404810B2 (en) * | 2006-02-17 | 2013-03-26 | Five Prime Therapeutics, Inc. | Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma |
| EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| CN102203290B (zh) * | 2008-10-27 | 2015-05-06 | 北海道公立大学法人札幌医科大学 | 肿瘤干细胞分子标记 |
| EP3345920A1 (en) | 2009-10-26 | 2018-07-11 | Externautics S.p.A. | Breast tumor markers and methods of use thereof |
| WO2011051276A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Colon and rectal tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| EP2494361B2 (en) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Ovary tumor markers and methods of use thereof |
| EP2493916B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| FR2973380B1 (fr) * | 2011-04-01 | 2018-02-09 | C.Ris Pharma | Peptides isoles et purifies a partir de testicules de roussette |
| HRP20230443T1 (hr) | 2011-05-24 | 2023-09-15 | BioNTech SE | Individualizirana cjepiva protiv raka |
| TW201302800A (zh) * | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| AU2013351542B2 (en) | 2012-11-28 | 2018-08-09 | BioNTech SE | Individualized vaccines for cancer |
| JP2016502499A (ja) * | 2012-12-04 | 2016-01-28 | オンコセラピー・サイエンス株式会社 | Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2016040682A1 (en) | 2014-09-10 | 2016-03-17 | Genentech, Inc. | Immunogenic mutant peptide screening platform |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CA3008641A1 (en) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| US20250161411A1 (en) * | 2021-12-27 | 2025-05-22 | Memorial Sloan-Kettering Cancer Center | Tumor mhc class i expression is associated with interleukin-2 response in melanoma |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| AU7516494A (en) * | 1993-07-29 | 1995-02-28 | Isis Pharmaceuticals, Inc. | Oligomers for modulating human immunodeficiency virus |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| SE508004C2 (sv) | 1996-08-07 | 1998-08-10 | Intermec Ptc Ab | Arrangemang för automatisk inställning av printrar samt material därtill |
| AU6337398A (en) * | 1997-02-24 | 1998-09-09 | Genetics Institute Inc. | Secreted proteins and polynucleotides encoding them |
| AU7549498A (en) * | 1997-06-03 | 1998-12-21 | Protegene Inc. | Human proteins having transmembrane domains and dnas encoding these prot eins |
| CA2316182A1 (en) * | 1998-02-09 | 1999-08-12 | Genset S.A. | Cdnas encoding secreted proteins |
| EP1144444A3 (en) * | 1998-12-22 | 2002-01-02 | Genset | Dnas encoding proteins with signal sequences |
| CA2368098A1 (en) * | 1999-06-25 | 2001-01-04 | Genset S.A. | Complementary dna's encoding proteins with signal peptides |
| WO2001054472A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU2001241541A1 (en) * | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| AU2001251259A1 (en) * | 2000-04-07 | 2001-10-23 | Senomyx, Inc. | Novel signal transduction molecules |
| JP2004517604A (ja) * | 2000-05-18 | 2004-06-17 | インサイト・ゲノミックス・インコーポレイテッド | Ｇタンパク質結合受容体 |
| JP2002112793A (ja) * | 2000-08-04 | 2002-04-16 | Japan Science & Technology Corp | 新規ｇ蛋白質共役受容体 |
| AU2001288237A1 (en) * | 2000-08-07 | 2002-02-18 | Curagen Corporation | Proteins and nucleic acids encoding g-protein coupled receptors |
| EP1326973A2 (en) * | 2000-10-04 | 2003-07-16 | Bayer Aktiengesellschaft | Regulation of human gpcr-like protein |
| AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| CA2460621A1 (en) * | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| WO2003059148A2 (en) * | 2001-12-21 | 2003-07-24 | Gene Logic, Inc. | Gene expression profiles in stomach cancer |
| GB0203419D0 (en) * | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
| US20030170639A1 (en) * | 2002-03-11 | 2003-09-11 | Youmin Shu | Liver transmembrane protein gene |
| DE10211088A1 (de) | 2002-03-13 | 2003-09-25 | Ugur Sahin | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP2261368A1 (en) * | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2003263660A1 (en) * | 2003-08-29 | 2005-03-16 | Pantarhei Bioscience B.V. | Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood |
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
-
2003
- 2003-09-26 DE DE10344799A patent/DE10344799A1/de not_active Withdrawn
-
2004
- 2004-09-23 CA CA2539837A patent/CA2539837C/en not_active Expired - Lifetime
- 2004-09-23 EP EP10009743.5A patent/EP2266608B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009746A patent/EP2267011A3/de not_active Withdrawn
- 2004-09-23 EP EP10009759A patent/EP2266617A3/de not_active Withdrawn
- 2004-09-23 EP EP10009753.4A patent/EP2267012B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009745A patent/EP2266610A3/de not_active Withdrawn
- 2004-09-23 CA CA3096188A patent/CA3096188C/en not_active Expired - Lifetime
- 2004-09-23 EP EP10009750.0A patent/EP2266612B1/de not_active Expired - Lifetime
- 2004-09-23 ES ES10009753.4T patent/ES2634705T3/es not_active Expired - Lifetime
- 2004-09-23 EP EP10009754.2A patent/EP2267013B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009751.8A patent/EP2266613B1/de not_active Expired - Lifetime
- 2004-09-23 EP EP10009761A patent/EP2266618A3/de not_active Withdrawn
- 2004-09-23 EP EP10009757A patent/EP2266615A3/de not_active Withdrawn
- 2004-09-23 EP EP10009758A patent/EP2266616A3/de not_active Withdrawn
- 2004-09-23 EP EP04786996.1A patent/EP1664113B1/de not_active Expired - Lifetime
- 2004-09-23 AU AU2004275500A patent/AU2004275500B2/en not_active Expired
- 2004-09-23 EP EP10009747A patent/EP2295077A3/de not_active Withdrawn
- 2004-09-23 EP EP10009760A patent/EP2267014A3/de not_active Withdrawn
- 2004-09-23 US US10/573,229 patent/US7875424B2/en active Active
- 2004-09-23 EP EP10009763A patent/EP2272534A3/de not_active Withdrawn
- 2004-09-23 CA CA2984653A patent/CA2984653C/en not_active Expired - Lifetime
- 2004-09-23 EP EP10009748A patent/EP2332979A3/de not_active Withdrawn
- 2004-09-23 EP EP10009752A patent/EP2266614A3/de not_active Withdrawn
- 2004-09-23 EP EP10009749A patent/EP2266611A3/de not_active Withdrawn
- 2004-09-23 JP JP2006527354A patent/JP5144933B2/ja not_active Expired - Lifetime
- 2004-09-23 CA CA2814269A patent/CA2814269C/en not_active Expired - Lifetime
- 2004-09-23 EP EP10009744A patent/EP2266609A3/de not_active Withdrawn
- 2004-09-23 EP EP10009755A patent/EP2332981A3/de not_active Withdrawn
- 2004-09-23 WO PCT/EP2004/010697 patent/WO2005030250A2/de not_active Ceased
- 2004-09-23 EP EP10009762A patent/EP2332983A3/de not_active Withdrawn
- 2004-09-23 EP EP10009756A patent/EP2332980A3/de not_active Withdrawn
-
2010
- 2010-12-16 US US12/969,754 patent/US20110135640A1/en not_active Abandoned
-
2011
- 2011-11-21 JP JP2011253535A patent/JP5639989B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-09 JP JP2012223869A patent/JP5804519B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-16 US US13/863,780 patent/US9139880B2/en not_active Expired - Lifetime
-
2014
- 2014-06-02 JP JP2014113690A patent/JP5969538B2/ja not_active Expired - Lifetime
-
2015
- 2015-08-19 US US14/830,506 patent/US9267177B2/en not_active Expired - Lifetime
- 2015-09-09 US US14/849,052 patent/US9733251B2/en not_active Expired - Lifetime
-
2016
- 2016-02-18 US US15/046,700 patent/US9910043B2/en not_active Expired - Lifetime
- 2016-05-10 JP JP2016094337A patent/JP6196350B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007506417A5 (OSRAM) | ||
| JP2008537546A5 (OSRAM) | ||
| JP2007537197A5 (OSRAM) | ||
| JP2006516190A5 (OSRAM) | ||
| JP5498018B2 (ja) | 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害 | |
| JP2010047597A5 (OSRAM) | ||
| RU2008114318A (ru) | Идентификация опухолевых антигенов для диагностики и терапии | |
| US20070112179A1 (en) | Novel compounds | |
| EP2682475A1 (en) | Antibody and antigen recognizing tumor-initiating cells and use thereof | |
| CN107028969A (zh) | 用于癌症诊断和治疗的方法和组合物 | |
| JP2005519608A5 (OSRAM) | ||
| JP2007526759A5 (OSRAM) | ||
| JP2001522238A (ja) | 胃腸管の疾患の検出に有用な試薬および方法 | |
| CN114650842A (zh) | 抗tim-3抗体 | |
| JP2008527998A (ja) | Ｎｓｃｌｃの診断のためのｇｉｔｒ抗体 | |
| JP2003521244A5 (OSRAM) | ||
| US20070269452A1 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
| MX2012012735A (es) | Deteccion y modulacion de formacion de vasos linfaticos mediados por la proteina slit y roundabount (robo), y usos de los mismos. | |
| JP2001526546A (ja) | 肺の疾患の検出に有用な試薬および方法 | |
| US20220363767A1 (en) | Hla-h, hla-j, hla-l, hla-v and hla-y as therapeutic and diagnostic targets | |
| JP2012525121A5 (OSRAM) | ||
| CN101161283B (zh) | CMTM1-v17的新应用及其拮抗剂 | |
| JP2012525121A (ja) | 診断および治療のための腫瘍関連マーカーの同定 | |
| US7641902B2 (en) | Compositions and methods for detecting cancer and for inhibiting metastasis | |
| EP1705487A2 (en) | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |